Drug intelligence / Profile preview

BAY1193397

Development stage: Phase 2
Lead developer: Bayer
Modality: Small Molecules
Administration: Oral

Overview

BAY1193397 is an investigational small molecule drug developed as an oral antagonist of the alpha-2C adrenergic receptor (ADRA2C). Its primary mechanism of action is to block the alpha-2C adrenoreceptor, which plays a role in regulating blood flow and microcirculation. The drug was developed for the treatment of diabetic foot ulcers, with clinical studies focusing on its effects on skin capillary blood flow and transcutaneous oxygen pressure in patients with type II diabetes. Pharmacokinetic studies have shown that BAY1193397 is rapidly absorbed after oral administration, has a terminal half-life of 17–20 hours, and demonstrates dose-proportional exposure. Clinical trials have indicated that it is generally safe and well tolerated.

Other names: BAY 1193397BAY1193397BAY-1193397

Targets

ADRA2C (α2C)

Beyond the preview

Go deeper on BAY1193397.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BAY1193397.

Explore the full profile